Trial · NCT01973140
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Plasma Osmolarity With Tolvaptan | 22 hours | Blood samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. Plasma osmolarity was measured from the blood samples. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Primary | Change in Plasma Osmolarity With 3% Saline Infusion | 10 hours | Baseline data for visit 1 and visit 2 were collected separately at the start of each visit, this Outcome Measure is reporting data from the baseline collected at visit 2. Samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, and 10 hours post baseline. Plasma osmolarity was measured from the blood samples. |
| Primary | Change in Plasma Sodium With Tolvaptan | 22 hours | Blood samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. Plasma sodium was measured from the blood samples. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Primary | Change in Plasma Sodium With 3% Saline Infusion | 10 hours | Blood samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, and 10 hours post baseline. Plasma sodium was measured from the blood samples. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Plasma Vasopressin With Tolvaptan | 22 hours | Blood samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. Plasma vasopressin was measured from the blood samples. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Plasma Vasopressin With 3% Saline Infusion | 10 hours | Blood samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, and 10 hours post baseline. Plasma vasopressin was measured from the blood samples. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Urine Osmolarity With Tolvaptan | 22 hours | Urine samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. Urine osmolarity was measured from the urine samples. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Urine Osmolarity With 3% Saline Infusion | 10 hours | Urine samples were collected at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, and 10 hours post baseline. Urine osmolarity was measured from the urine samples. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Thirst Ratings With Tolvaptan | 6 hours | Participants were asked to rate their thirst at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline. The participants were instructed to rate their thirst on a scale from 0-10 with a higher number indicating a higher level of thirst. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Thirst Ratings With 3% Saline Infusion | 6 hours | Participants were asked to rate their thirst at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline. The participants were instructed to rate their thirst on a scale from 0-10 with a higher number indicating a higher level of thirst. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Fluid Intake Volume With Tolvaptan | 22 hours | For the first six hours, participants ingested water in prescribed amounts. For the remaining 16 hours, fluid intake was unrestricted but the volumes of fluids ingested was recorded. Fluid intake was recorded 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Fluid Intake Volume With 3% Saline Infusion | 10 hours | Subjects were not allowed to drink until the end of the 6-hour infusion. After that time, they were allowed to drink freely, and intake was recorded as volume each hour for the next 4 hours. So, the values recorded at 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline are the volume of the infusion, while the values recorded at 8 hours post baseline and 10 hours post baseline are the volumes the participants chose to drink freely. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Fluid Intake Volume Per kg Body Weight With Tolvaptan | 22 hours | For the first six hours, participants ingested water in prescribed amounts. For the remaining 16 hours, fluid intake was unrestricted but the volumes of fluids ingested and weight was recorded. Volume of fluids ingested and weight was recorded 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Fluid Intake Volume Per kg Body Weight With 3% Saline Infusion | 6 hours | Subjects were not allowed to drink until the end of the 6 hour infusion and were weighed each hour. So, the values recorded at 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline are the volume of the infusion per kg of body weight. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Urine Volume With Tolvaptan | 22 hours | For the first six hours, participants ingested water in prescribed amounts. For the remaining 16 hours, fluid intake was unrestricted. The volume of urine was recorded at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Urine Volume With 3% Saline Infusion | 10 hours | Subjects were not allowed to drink until the end of the 6 hour infusion. After that time, they were allowed to drink freely. Urine was recorded as volume each hour at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, and 10 hours post baseline. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Urine Volume Per kg Body Weight With Tolvaptan | 22 hours | For the first six hours, participants ingested water in prescribed amounts. For the remaining 16 hours, fluid intake was unrestricted. The volume of urine and weight were recorded at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Urine Volume Per kg Body Weight With 3% Saline Infusion | 6 hours | Subjects were not allowed to drink until the end of the 6-hour infusion. Urine volume and weight were recorded at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
| Secondary | Change in Body Weight With Tolvaptan | 22 hours | For the first six hours, participants ingested water in prescribed amounts. For the remaining 16 hours, fluid intake was unrestricted. The participant's weight was recorded at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, 6 hours post baseline, 8 hours post baseline, 10 hours post baseline, 14 hours post baseline, and 22 hours post baseline. This Outcome Measure is reporting the data from the first visit when participants were given tolvaptan. |
| Secondary | Change in Body Weight With 3% Saline Infusion | 6 hours | Subjects were not allowed to drink until the end of the 6-hour infusion. After that time, they were allowed to drink freely. Participant's weight was recorded at baseline, 1 hour post baseline, 2 hours post baseline, 3 hours post baseline, 4 hours post baseline, 5 hours post baseline, and 6 hours post baseline. This Outcome Measure is reporting the data from the second visit when participants were given 3% saline infusion. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01973140/registered